In Reply Dr Roehm requests more information about the gallbladder disease outcome in the WHI trials. The goal of our article was to provide a comprehensive, integrated overview of findings from the 2 hormone therapy trials, including results from extended postintervention follow-up.
Due to the large number of outcomes presented (including primary and secondary adjudicated end points and quality-of-life outcomes), we only had space to present age-stratified analyses for the primary and secondary outcomes. We presented the hazard ratio (HR) for gallbladder disease in the overall cohort for each trial and noted that no significant differences by age group were observed.
Manson JE, Chlebowski RT, Aragaki AK. Hormone Therapy Use and Outcomes in the Women’s Health Initiative Trials—Reply. JAMA. 2014;311(4):417-418. doi:10.1001/jama.2013.285163